ClinicalTrials.gov
ClinicalTrials.gov Menu

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01426880
Recruitment Status : Completed
First Posted : September 1, 2011
Last Update Posted : February 15, 2016
Sponsor:
Collaborators:
TEVA
Roche Pharma AG
GlaxoSmithKline
Information provided by (Responsible Party):
German Breast Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 2013
  Actual Study Completion Date : August 2013
Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):